# Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

> **NCT06429761** · PHASE4 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 100 (estimated)

## Conditions studied

- BREAST CANCER

## Interventions

- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT06429761
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-02
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429761, "Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06429761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*